: The drug targets a specific protein called USAG-1 (uterine sensitization-associated gene-1). In nature, USAG-1 acts as a "biological parking brake" that prevents dormant tooth buds in the human jaw from developing into full teeth after the adult set has grown.
: Launched in September 2024 at Kyoto University Hospital. This phase involves 30 healthy adult males aged 30–64 who are missing at least one molar, primarily focusing on safety and dosage. NEWM-035
The code appears to be a misnomer or a very specific internal project identifier for which there is no broad public record. However, it is most frequently associated in recent medical research contexts with TRG-035 , a groundbreaking tooth regeneration drug currently undergoing human clinical trials in Japan. : The drug targets a specific protein called